title: Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome.
authors.forename: S
authors.initials: S
authors.lastname: Sciascia
authors.forename: C
authors.initials: C
authors.lastname: Naretto
authors.forename: D
authors.initials: D
authors.lastname: Rossi
authors.forename: M
authors.initials: M
authors.lastname: Bazzan
authors.forename: D
authors.initials: D
authors.lastname: Roccatello
mesh_terms: D017152:Antibodies, Antiphospholipid / Q000097:blood*; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D000925:Anticoagulants / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000097:blood / Q000276:immunology* / Q000628:therapy*; D015536:Down-Regulation; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D010976:Platelet Count; D000069283:Rituximab; D013921:Thrombocytopenia / Q000097:blood / Q000628:therapy; D055815:Young Adult
chemical_list: D017152:Antibodies, Antiphospholipid; D058846:Antibodies, Monoclonal, Murine-Derived; D000925:Anticoagulants; D007166:Immunosuppressive Agents; D000069283:Rituximab